Palvella Therapeutics (PVLA) Other financing activities (2013 - 2026)
Palvella Therapeutics' (PVLA) quarterly Other financing activities came in at $14.2 million in Q1 2026, up 21164.18% year-on-year from N/an in Q1 2025, and up 13468.57% on a QoQ basis from $105000.0 in Q4 2025.
Palvella Therapeutics (PVLA) Other financing activities (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 13 years of Other financing activities data on file, last reported at $14.2 million in Q1 2026.
- On a quarterly basis, Other financing activities rose 21164.18% year-over-year to $14.2 million in Q1 2026; TTM through Mar 2026 was $14.9 million, a 75.12% decrease from a year earlier, with the FY2025 full-year figure at $763000.0, down 98.73% from the prior year.
- Other financing activities for Q1 2026 stood at $14.2 million, up from $105000.0 in the prior quarter.
- Over the last five years, Other financing activities for PVLA reached as high as $60.0 million in Q4 2024 and fell as low as -$52000.0 in Q4 2023.
- Historically, Other financing activities has averaged $6.3 million across 5 years, with a median of $93500.0 in 2022.
- Across the five-year window, Other financing activities sank 150.98% in 2023 and soared 115486.54% in 2024, its largest moves.
- Year by year, Other financing activities stood at $102000.0 in 2022, then sank by 150.98% to -$52000.0 in 2023, then surged by 115486.54% to $60.0 million in 2024, then slumped by 99.83% to $105000.0 in 2025, then soared by 13468.57% to $14.2 million in 2026.
- Per Business Quant data, the three most recent Other financing activities figures were $14.2 million in Q1 2026, $105000.0 in Q4 2025, and $242000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.25 Mn |
| Mar 31, 2026 | 14.25 Mn |
| Dec 31, 2025 | 105,000.00 |
| Dec 31, 2025 | 105,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Sep 30, 2025 | 242,000.00 |
| Jun 30, 2025 | 349,000.00 |
| Jun 30, 2025 | 349,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | 60.00 Mn |
| Dec 31, 2024 | 60.00 Mn |
| Dec 31, 2023 | -52,000.00 |
| Dec 31, 2023 | -52,000.00 |
| Jun 30, 2023 | 52,000.00 |
| Jun 30, 2023 | 52,000.00 |
| Dec 31, 2022 | 102,000.00 |
| Dec 31, 2022 | 102,000.00 |
| Sep 30, 2022 | -9,000.00 |
| Sep 30, 2022 | -9,000.00 |